The combination regimen comprising gemcitabine and nab*-paclitaxel (GNP) exhibited similar potential with FOLFIRINOX** in downstaging and improving survival rates in pancreatic cancer, according to several studies presented at the ASCO Gastrointestinal Cancers Symposium 2018 (ASCO GI 2018).
A weekly dose escalation of regorafenib was superior to starting with the standard dose of 160 mg/day for patients with refractory metastatic colorectal cancer (mCRC), according to the ReDOS* trial presented at the ASCO GI Cancers Symposium 2018.
Cabozantinib, an oral inhibitor of multiple tyrosine kinases, significantly improves overall survival (OS) and progression-free survival (PFS) in patients with advanced hepatocellular carcinoma (HCC) whose disease progressed following sorafenib or other systemic therapies.
Pembrolizumab demonstrated promising results in several outcomes among patients with advanced hepatocellular carcinoma (HCC) whose disease progressed on or who were unable to tolerate treatment with sorafenib, findings from the KEYNOTE-224* trial show.
The combination of nivolumab and ipilimumab demonstrated strong response, progression-free survival (PFS), and overall survival (OS) rates in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic or recurrent colorectal cancer (CRC), results from the phase II CheckMate-142* trial show.
The addition of ramucirumab, a fully human IgG1 monoclonal antibody receptor antagonist, to chemotherapy, prolonged progression-free survival (PFS) in individuals with previously untreated metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma, findings from the phase III RAINFALL* trial show.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Multiple intralesional injections with purified protein derivative (PPD) leads to faster clearance of common warts compared with a single injection, although the latter is better tolerated, as shown in the results of an open‐label, superiority trial.
Use of direct acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection is feasible during pregnancy, as these drugs are highly effective and treatment duration is relatively short, according to a study. In addition, DAA treatment helps improve maternal health and prevent vertical transmission.